Clinical Trial: The KN510713 Study in Combination With mFOLFIRINOX

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07114861) titled 'The KN510713 Study in Combination With mFOLFIRINOX' on July 23.

Brief Summary: This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).

Study Start Date: Oct. 22

Study Type: INTERVENTIONAL

Condition: Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Intervention: DRUG: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX

KN510 120mg/day + KN713 90mg/day: once daily in 14-d...